Obizur FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved October 23, 2014)
Brand name: Obizur
Generic name: antihemophilic factor (recombinant)
Company: Baxter International Inc.
Treatment for: Hemophilia A
Obizur (antihemophilic factor [recombinant]) is an antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
Development timeline for Obizur
|Oct 24, 2014||Approval FDA Approves Obizur [Antihemophilic Factor (Recombinant)] for Acquired Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.